PERZINFOTEL

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H13N2O5P
Molecular Weight	260.1837
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OP(O)(=O)CCN1CCCNC2=C1C(=O)C2=O

InChI

InChIKey=BDABGOLMYNHHTR-UHFFFAOYSA-N

InChI=1S/C9H13N2O5P/c12-8-6-7(9(8)13)11(3-1-2-10-6)4-5-17(14,15)16/h10H,1-5H2,(H2,14,15,16)

HIDE SMILES / InChI

Molecular Formula	C9H13N2O5P
Molecular Weight	260.1837
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=685790&p_IsPs=N

Perzinfotel (EAA-090) is a novel squaric acid amide derivative that has been identified as a potential treatment for ischemic brain damage resulting from stroke. EAA-090 is a competitive inhibitor at the NMDA-selective subtype of the glutamate receptor. The compound demonstrates potent inhibitory activity in both in vitro and in vivo models of NMDA-induced excitotoxicity and provides neuroprotective efficacy in several animal models of stroke. EAA-090 is unique among competitive NMDA antagonists in displaying a clear separation between predicted efficacious dose and doses that induce PCP-like psychotomimetic side effects in both animals and humans. This unique profile makes EAA-090 an exciting candidate for assessing the neuroprotective potential of the competitive NMDA mechanism.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
NMDA selective glutamate receptor complex 1 Target ID: GO:0017146 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9457246	Antagonist 2849		28.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Stroke 144 Sources: http://adisinsight.springer.com/drugs/800009946	Primary		Preclinical	Unknown Approved Use Unknown
Neuropathic pain 26 Sources: http://adisinsight.springer.com/drugs/800009946	Palliative		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1210 ng/mL OTHER GOV https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		MIDOSTAURIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
15700 ng × h/mL OTHER GOV https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		MIDOSTAURIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
20 h OTHER GOV https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		MIDOSTAURIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf			MIDOSTAURIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf	Disc. AE: Renal insufficiency... AEs leading to discontinuation/dose reduction: Renal insufficiency (grade 3-4, 2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf
50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	Disc. AE: Transaminases increased, Rash... AEs leading to discontinuation/dose reduction: Transaminases increased (4 patients) Rash (3 patients) Vomiting (3 patients) Arrhythmia (2 patients) Myocardial ischemia (2 patients) Nausea (2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf
300 mg 2 times / day multiple, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf

AEs

AE	Significance	Dose	Population
Renal insufficiency	grade 3-4, 2 patients Disc. AE	50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf
Arrhythmia	2 patients Disc. AE	50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf
Myocardial ischemia	2 patients Disc. AE	50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf
Nausea	2 patients Disc. AE	50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf
Rash	3 patients Disc. AE	50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf
Vomiting	3 patients Disc. AE	50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf
Transaminases increased	4 patients Disc. AE	50 mg 2 times / day steady, oral Recommended Dose: 50 mg, 2 times / day Route: oral Route: steady Dose: 50 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	unhealthy, 47 years (range: 18-60 years) Health Status: unhealthy Age Group: 47 years (range: 18-60 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438 inducer 440	inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060 CYP2A6 879 CYP2B6 926 CYP3A4/5 296 P-gp 1741 BCRP 910 MRP2 499 OATP1B1 1079 OATP1B3 961 OAT1 725 OAT3 747	CYP1A2 1197 CYP2A6 626 CYP2B6 776 CYP2C8 810 CYP2C19 1119 CYP2E1 729 CYP3A5 446 CYP1A1 389 CYP3A 220 P-gp 2052 MRP2 252	CYP1A2 832 CYP2B6 669 CYP2C8 198 CYP2C19 329 CYP3A 142 MRP2 146

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no	CGP52421 1
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no	CGP62221 1
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no	CGP52421 1
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no	CGP62221 1
MRP2 625	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no	CGP52421 1
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no	CGP62221 1
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no	CGP52421 1
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	no	CGP62221 1
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 0.5 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 0.5 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 0.5 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 1 uM]	CGP62221 1
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 1 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 1.5 uM]	CGP62221 1
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes [IC50 1.5 uM]
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes [IC50 1.7 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 3 uM]
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes [IC50 5 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 5 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 5 uM]	CGP62221 1
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 5 uM]	CGP52421 1
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes [IC50 5 uM]
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
CYP2C19 2141	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes
CYP2C19 2141	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2C19 2141	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
CYP2C8 1117	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes
CYP2C8 1117	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2C8 1117	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP52421 1
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes	CGP62221 1
MRP2 625	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=8 Page: 8.0	yes
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes	CGP52421 1
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes	CGP62221 1
PXR 51	activator 342 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes
PXR 51	activator 342 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes	CGP52421 1
PXR 51	activator 342 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=32 Page: 32.0	yes	CGP62221 1

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	major	CGP52421 1
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	major	CGP62221 1
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
CYP2A6 626	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
CYP2B6 776	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
CYP2E1 729	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
MRP2 252	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	no
CYP1A1 389	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	yes	CGP52421 1
CYP1A1 389	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	yes	CGP62221 1
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	yes	CGP62221 1
CYP3A 220	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	yes	CGP52421 1
CYP3A 220	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=31 Page: 31.0	yes	CGP62221 1
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=7 Page: 7.0	yes		yes (co-administration study) Comment: Coadministration of ketoconazole (400 mg daily for 10 days) with a single dose of Rydapt (50 mg) on Day 6 increased AUCinf of midostaurin by 10.4-fold and CGP62221 by 3.5-fold and area under the curve over time to last measurable concentrations (AUC0-t) of CGP52421 by 1.2-fold compared to a single Rydapt dose coadministered with placebo. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf#page=7 Page: 7.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000PharmR.pdf#page=2 Page: 2.0

Sourcing

Vendor/Aggregator	ID	URL
Chem Scene	CS-0014908	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0014908
Compound Cloud	6918236
eMolecules	36772575	https://orderbb.emolecules.com/search/#?query=36772575
mcule	MCULE-6354289466	https://mcule.com/MCULE-6354289466/
MedChem Express	HY-19168	https://www.medchemexpress.com/search.html?q=HY-19168&ft=&fa=&fp=
MuseChem	I008642	https://www.musechem.com/product/I008642.html

PubMed

Title	Date	PubMed
Effects of perzinfotel, butorphanol tartrate, and a butorphanol-perzinfotel combination on the minimum alveolar concentration of isoflurane in cats.	2010-11	21034317
Effects of perzinfotel on the minimum alveolar concentration of isoflurane in dogs when administered as a preanesthetic via various routes or in combination with butorphanol.	2010-06	20513173
Effects of intravenous administration of perzinfotel, fentanyl, and a combination of both drugs on the minimum alveolar concentration of isoflurane in dogs.	2009-12	19951116
Prodrugs of perzinfotel with improved oral bioavailability.	2009-02-12	19146418
Functional identification of NR2 subunits contributing to NMDA receptors on substance P receptor-expressing dorsal horn neurons.	2008-10-10	18847474
Effects of perzinfotel on the minimum alveolar concentration of isoflurane in dogs.	2007-12	18052733
Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity.	2005-06	15764736

Patents

Sample Use Guides

In Vivo Use Guide

30-100 mg/kg orally (rats) 10-30 mg/kg intravenous (dogs)

Route of Administration: Oral

In Vitro Use Guide

IC50 28 nM (inhibited [(3)H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid binding to NMDA receptors). IC50 477 nM (decreased the duration of spontaneous synaptic currents and inhibited NMDA-activated currents in rat hippocampal neurons).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:30:16 GMT 2025` Edited by `admin` on `Mon Mar 31 18:30:16 GMT 2025`
Record UNII	FX5AUU7Z8T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EAA-090

Preferred Name

English

PERZINFOTEL

Official Name

English

perzinfotel [INN]

Common Name

English

[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid

Systematic Name

English

PERZINFOTEL [USAN]

Common Name

English

PHOSPHONIC ACID, (2-(8,9-DIOXO-2,6-DIAZABICYCLO(5.2.0)NON-1(7)-EN-2-YL)ETHYL)-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1509